Journal
CANCERS
Volume 11, Issue 3, Pages -Publisher
MDPI
DOI: 10.3390/cancers11030380
Keywords
liquid biopsy; circulating tumour cells; non-small cell lung cancer; actionable mutations
Categories
Funding
- Cancer Australia [APP1145657]
- NHMRC Early Career Fellowship [1157741]
- National Health and Medical Research Council of Australia [1157741] Funding Source: NHMRC
Ask authors/readers for more resources
Objectives: In non-small cell lung cancers (NSCLC), tumour biopsy can often be an invasive procedure. The development of a non-invasive methodology to study genetic changes via circulating tumour cells (CTCs) is an appealing concept. Whilst CTCs typically remain as rare cells, improvements in epitope-independent CTC isolation techniques has given rise to a greater capture of CTCs. In this cross sectional study, we demonstrate the capture and characterization of NSCLC CTCs for the clinically actionable markers epidermal growth factor receptor (EGFR) alterations, anaplastic lymphoma kinase (ALK) rearrangements and programmed death ligand-1 (PD-L1) expression. The study identified CTCs/CTC clusters in 26/35 Stage IV NSCLC patients, and subsequently characterized the CTCs for EGFR mutation, ALK status and PD-L1 status. This pilot study demonstrates the potential of a non-invasive fluid biopsy to determine clinically relevant biomarkers in NSCLC.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available